Key Highlights: Implications: Zytorvi’s approval strengthens Dr. Reddy’s position in India’s esophageal cancer market by expanding access to first-line PD-1 immunotherapy without PD-...
Key Highlights: Implications: Mankind Pharma’s €48 million investment for a 70% stake in ACTx signals a strategic shift toward high-value oncology and next-generation CAR-T therapies. ACTx...
Key Highlights: Implications: Dr. Reddy’s launch of Nivorz marks its entry into India’s biosimilar immuno‑oncology segment and adds a lower‑cost checkpoint inhibitor option across 12 appro...
Key Highlights: Implications: The approval broadens AstraZeneca’s trastuzumab deruxtecan franchise in India from later-line metastatic use into the earlier, potentially larger HER2-positiv...
Key Highlights: Implications: Relopduo gives BMS a next‑generation immunotherapy in India’s melanoma market, combining PD‑1 and LAG‑3 blockade to offer materially better pro...
Key Highlights: Implications: Tecentriq’s 7‑minute under‑the‑skin version should help Roche deepen its lung cancer business in India by easing pressure on overcrowded infusion centers...
